Annamycin is a small molecule commercialized by Moleculin Biotech, with a leading Phase II program in Refractory Acute Myeloid Leukemia;Relapsed Acute Myeloid Leukemia. According to Globaldata, it is involved in 11 clinical trials, of which 5 were completed, 2 are ongoing, 3 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Annamycin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Annamycin is expected to reach an annual total of $183 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Annamycin Overview
L-Annamycin is under development for the treatment of relapsed or refractory acute myelogeneous leukemia (AML), metastatic lung cancer, metastatic melanoma, soft-tissue sarcomas with pulmonary metastases, metastatic lung sarcoma, reticulosarcoma, metastatic pancreatic cancer (liver mets/pancreatic), liposarcoma, leiomyosarcoma, synovial sarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, malignant peripheral nerve sheath tumour, malignant solitary fibrous tumour, and pleomorphic RMS and metastatic osteosarcoma. The drug candidate is administered intravenously. L-Annamycin is a liposome nanoparticle formulation of annamycin, a second generation anthracycline. It is a liposome-encapsulated form of the semi-synthetic doxorubicin analogue annamycin with antineoplastic activity. It acts by targeting DNA topoisomerase II alpha and beta. It was under development for the treatment of relapsed and refractory acute lymphocytic leukemia (ALL).
Moleculin Biotech Overview
Moleculin Biotech (MBI) is a clinical-stage pharmaceutical company that primarily focuses on developing therapeutic candidates for hard-to-treat tumors and viruses. The company’s lead program, annamycin, develops for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The company’s portfolio also includes WP1066, an immune and transcription modulator for targeting various cancers, and WP1122, an antimetabolite for potential treatment of viruses and certain cancer indications. MBI products are primarily aimed at patients suffering from specific types of cancer and viral diseases. The company primarily operates in the U.S. MBI is headquartered in Houston, Texas, the US.
The operating loss of the company was US$30.1 million in FY2023, compared to an operating loss of US$30.6 million in FY2022. The net loss of the company was US$29.8 million in FY2023, compared to a net loss of US$29 million in FY2022.
For a complete picture of Annamycin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.